Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study - Results at 6 and 12 Months From a Retrospective Multi-centric Study

This study investigated the effectiveness and safety of SoracteLite ™- Trans-Perineal Laser ablation (TPLA) in the treatment of patients with symptomatic Benign Prostatic Hyperplasia (BPH) at 6 and 12 months follow-up

The purpose of this study was to investigate the effectiveness and safety of SoracteLite ™ - Trans-Perineal Laser ablation (TPLA) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) at 6 and 12 months follow-up. Methods: Patients with urinary symptoms secondary to BPH underwent TPLA under local anaesthesia in four centers. Under US guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment was performed with diode laser operating at 1064 nm changing the illumination time according to prostate size.

Inclusion Criteria:

• Male
• ≥ 50 years of age
• International Prostate Symptoms (IPSS) ≥12
• Peak urinary flow rate (Qmax): <15 ml
• Prostate volume: ≥ 30 ml, measured by transrectal ultrasound
• Post-void residual (PVR): <400 ml
• Signed informed consent

Exclusion Criteria:

• MRI signs of malignancy confirmed by biopsy investigation
• urethral stenosis
• serious coagulation disorders
• inadequate compliance
• ischemic pathology in the previous six months
• active phase inflammatory pathology